Xencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor Fitzgerald

Key Points

• Xencor (NASDAQ:XNCR) has been upgraded to a "strong-buy" rating by Cantor Fitzgerald, with projected earnings per share of ($2.61) for FY2025 and ($3.55) for FY2026.
• Analyst ratings for Xencor vary, with one strong buy, seven buy ratings, one hold, and two sell ratings, leading to a consensus target price of $24.22.
• Despite its challenges, the company reported a revenue increase of 82.4% year-over-year, reaching $43.61 million in its last quarter, outperforming estimates.

Xencor (NASDAQ:XNCR - Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald to a "strong-buy" rating in a research note issued to investors on Wednesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Xencor's FY2025 earnings at ($2.61) EPS and FY2026 earnings at ($3.55) EPS.

Several other research analysts also recently weighed in on XNCR. Wells Fargo & Company dropped their target price on Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Wedbush restated an "outperform" rating and set a $26.00 target price on shares of Xencor in a research note on Tuesday, September 2nd. Bank of America downgraded Xencor from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $23.00 to $12.00 in a research note on Wednesday, September 3rd. Weiss Ratings restated a "sell (e+)" rating on shares of Xencor in a research note on Saturday, September 27th. Finally, Royal Bank Of Canada dropped their target price on Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and a consensus target price of $24.22.

Xencor Trading Up 3.1%

Shares of NASDAQ:XNCR opened at $12.40 on Wednesday. Xencor has a 12-month low of $6.92 and a 12-month high of $27.24. The business's fifty day simple moving average is $8.99 and its 200-day simple moving average is $9.04. The company has a market capitalization of $884.37 million, a PE ratio of -5.17 and a beta of 0.96.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. During the same period last year, the business posted ($1.07) EPS. The business's revenue was up 82.4% compared to the same quarter last year. Research analysts predict that Xencor will post -3.68 EPS for the current year.

Institutional Trading of Xencor

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in Xencor during the 1st quarter worth about $34,000. GAMMA Investing LLC increased its stake in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 1,449 shares in the last quarter. CWM LLC increased its stake in shares of Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares in the last quarter. AlphaQuest LLC purchased a new position in shares of Xencor in the 1st quarter valued at about $56,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 3,018 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.